{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:58:04Z","timestamp":1793213884542,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007458","name":"Qatar Foundation","doi-asserted-by":"publisher","award":["UREP28-173-3-057"],"award-info":[{"award-number":["UREP28-173-3-057"]}],"id":[{"id":"10.13039\/100007458","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Shenzhen, China"},{"DOI":"10.13039\/501100004252","name":"Qatar University","doi-asserted-by":"publisher","award":["RRC-2-032"],"award-info":[{"award-number":["RRC-2-032"]}],"id":[{"id":"10.13039\/501100004252","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rapid and accurate measurement of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)-specific neutralizing antibodies (nAbs) is paramount for monitoring immunity in infected and vaccinated subjects. The current gold standard relies on pseudovirus neutralization tests which require sophisticated skills and facilities. Alternatively, recent competitive immunoassays measuring anti-SARS-CoV-2 nAbs are proposed as a quick and commercially available surrogate virus neutralization test (sVNT). Here, we report the performance evaluation of three sVNTs, including two ELISA-based assays and an automated bead-based immunoassay for detecting nAbs against SARS-CoV-2. The performance of three sVNTs, including GenScript cPass, Dynamiker, and Mindray NTAb was assessed in samples collected from SARS-CoV-2 infected patients (n\u2009=\u2009160), COVID-19 vaccinated individuals (n\u2009=\u2009163), and pre-pandemic controls (n\u2009=\u200970). Samples were collected from infected patients and vaccinated individuals 2\u201324\u00a0weeks after symptoms onset or second dose administration. Correlation analysis with pseudovirus neutralization test (pVNT) and immunoassays detecting anti-SARS-CoV-2 binding antibodies was performed. Receiver operating characteristic (ROC) curve analysis was generated to assess the optimal threshold for detecting nAbs by each assay. All three sVNTs showed an excellent performance in terms of specificity (100%) and sensitivity (100%, 97.0%, and 97.1% for GenScript, Dynamiker, and Mindray, respectively) in samples collected from vaccinated subjects. GenScript demonstrated the strongest correlation with pVNT (<jats:italic>r<\/jats:italic>\u2009=\u20090.743, R<jats:sup>2<\/jats:sup>\u2009=\u20090.552), followed by Mindray (<jats:italic>r<\/jats:italic>\u2009=\u20090.718, R<jats:sup>2<\/jats:sup>\u2009=\u20090.515) and Dynamiker (<jats:italic>r<\/jats:italic>\u2009=\u20090.608, R<jats:sup>2<\/jats:sup>\u2009=\u20090.369). Correlation with anti-SARS-CoV-2 binding antibodies was variable, but the strongest correlations were observed between anti-RBD IgG antibodies and Mindray (<jats:italic>r<\/jats:italic>\u2009=\u20090.952, R<jats:sup>2<\/jats:sup>\u2009=\u20090.907). ROC curve analyses demonstrated excellent performance for all three sVNT assays in both groups, with an AUC ranging between 0.99 and 1.0 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Also, it was shown that the manufacturer's recommended cutoff values could be modified based on the tested cohort without significantly affecting the sVNT performance. The sVNT provides a rapid, low-cost, and scalable alternative to conventional neutralization assays for measuring and expanding nAbs testing across various research and clinical settings. Also, it could aid in evaluating actual protective immunity at the population level and assessing vaccine effectiveness to lay a foundation for boosters' requirements.<\/jats:p>","DOI":"10.1038\/s41598-022-21317-x","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T20:11:51Z","timestamp":1667938311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Evaluation of commercially available fully automated and ELISA-based assays for detecting anti-SARS-CoV-2 neutralizing antibodies"],"prefix":"10.1038","volume":"12","author":[{"given":"Hadeel T.","family":"Zedan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi M.","family":"Yassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duaa W.","family":"Al-Sadeq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamda","family":"Qotba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Nicolai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Pieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laith J.","family":"Abu-Raddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheyath K.","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"issue":"2","key":"21317_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3390\/pathogens10020161","volume":"10","author":"HT Al-Jighefee","year":"2021","unstructured":"Al-Jighefee, H. T. et al. Evaluation of antibody response in symptomatic and asymptomatic COVID-19 patients and diagnostic assessment of new IgM\/IgG ELISA kits. Pathogens 10(2), 161 (2021).","journal-title":"Pathogens"},{"key":"21317_CR2","unstructured":"CDC, U., Interim Guidelines for COVID-19 Antibody Testing. (2022) https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/lab\/resources\/antibody-tests-guidelines.html."},{"issue":"1","key":"21317_CR3","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1080\/22221751.2020.1835448","volume":"9","author":"B Meyer","year":"2020","unstructured":"Meyer, B. et al. Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT). Emerg. Microb. Infect. 9(1), 2394\u20132403 (2020).","journal-title":"Emerg. Microb. Infect."},{"issue":"2","key":"21317_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/clinchem\/hvaa262","volume":"67","author":"RT Suhandynata","year":"2021","unstructured":"Suhandynata, R. T. et al. Commercial serology assays predict neutralization activity against SARS-CoV-2. Clin. Chem. 67(2), 404\u2013414 (2021).","journal-title":"Clin. Chem."},{"issue":"1","key":"21317_CR5","first-page":"47","volume":"8","author":"NY-L Pang","year":"2021","unstructured":"Pang, N.Y.-L. et al. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Mil. Med. Res. 8(1), 47 (2021).","journal-title":"Mil. Med. Res."},{"issue":"6","key":"21317_CR6","doi-asserted-by":"publisher","first-page":"582","DOI":"10.3390\/v12060582","volume":"12","author":"N Younes","year":"2020","unstructured":"Younes, N. et al. Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2. Viruses 12(6), 582 (2020).","journal-title":"Viruses"},{"issue":"9","key":"21317_CR7","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","volume":"38","author":"CW Tan","year":"2020","unstructured":"Tan, C. W. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2\u2013spike protein\u2013protein interaction. Nat. Biotechnol. 38(9), 1073\u20131078 (2020).","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"21317_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/microorganisms9020245","volume":"9","author":"S Younes","year":"2021","unstructured":"Younes, S. et al. Diagnostic efficiency of three fully automated serology assays and their correlation with a novel surrogate virus neutralization test in symptomatic and asymptomatic SARS-COV-2 individuals. Microorganisms 9(2), 245 (2021).","journal-title":"Microorganisms"},{"key":"21317_CR9","unstructured":"Ismail, A. et al. Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays (2021)."},{"issue":"1","key":"21317_CR10","doi-asserted-by":"publisher","first-page":"e00247-21","DOI":"10.1128\/Spectrum.00247-21","volume":"9","author":"T Perkmann","year":"2021","unstructured":"Perkmann, T. et al. Anti-spike protein assays to determine SARS-CoV-2 antibody levels: A head-to-head comparison of five quantitative assays. Microbiol. Spectr. 9(1), e00247-21 (2021).","journal-title":"Microbiol. Spectr."},{"issue":"7","key":"21317_CR11","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1111\/trf.14116","volume":"57","author":"GK Nasrallah","year":"2017","unstructured":"Nasrallah, G. K. et al. Seroprevalence of hepatitis E virus among blood donors in Qatar (2013\u20132016). Transfusion 57(7), 1801\u20131807 (2017).","journal-title":"Transfusion"},{"issue":"12","key":"21317_CR12","doi-asserted-by":"publisher","first-page":"e0189033","DOI":"10.1371\/journal.pone.0189033","volume":"12","author":"MK Smatti","year":"2017","unstructured":"Smatti, M. K. et al. Prevalence and molecular profiling of Epstein Barr virus (EBV) among healthy blood donors from different nationalities in Qatar. PLoS ONE 12(12), e0189033 (2017).","journal-title":"PLoS ONE"},{"key":"21317_CR13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12985-016-0664-6","volume":"13","author":"AA Al-Qahtani","year":"2016","unstructured":"Al-Qahtani, A. A. et al. Prevalence of anelloviruses (TTV, TTMDV, and TTMV) in healthy blood donors and in patients infected with HBV or HCV in Qatar. Virol. J. 13, 208. https:\/\/doi.org\/10.1186\/s12985-016-0664-6 (2016).","journal-title":"Virol. J."},{"issue":"1","key":"21317_CR14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/jmv.24916","volume":"90","author":"GK Nasrallah","year":"2018","unstructured":"Nasrallah, G. K. et al. Estimating seroprevalence of herpes simplex virus type 1 among different Middle East and North African male populations residing in Qatar. J. Med. Virol. 90(1), 184\u2013190 (2018).","journal-title":"J. Med. Virol."},{"issue":"4","key":"21317_CR15","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.vaccine.2019.10.093","volume":"38","author":"MK Smatti","year":"2020","unstructured":"Smatti, M. K. et al. Measuring influenza hemagglutinin (HA) stem-specific antibody-dependent cellular cytotoxicity (ADCC) in human sera using novel stabilized stem nanoparticle probes. Vaccine 38(4), 815\u2013821 (2020).","journal-title":"Vaccine"},{"issue":"1","key":"21317_CR16","doi-asserted-by":"publisher","first-page":"11837","DOI":"10.1038\/s41598-021-91235-x","volume":"11","author":"GK Nasrallah","year":"2021","unstructured":"Nasrallah, G. K. et al. Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population. Sci. Rep. 11(1), 11837 (2021).","journal-title":"Sci. Rep."},{"key":"21317_CR17","doi-asserted-by":"crossref","unstructured":"Perera, R. A. P. M. et al. Evaluation of a SARS-CoV-2 surrogate virus neutralization test for detection of antibody in human, canine, cat and hamster sera. J. Clin. Microbiol. JCM.02504-20 (2020).","DOI":"10.1101\/2020.07.28.20163592"},{"issue":"2","key":"21317_CR18","doi-asserted-by":"publisher","first-page":"e02504-20","DOI":"10.1128\/JCM.02504-20","volume":"59","author":"APM Perera Ranawaka","year":"2021","unstructured":"Perera Ranawaka, A. P. M. et al. Evaluation of a SARS-CoV-2 surrogate virus neutralization test for detection of antibody in human, canine, cat, and hamster sera. J. Clin. Microbiol. 59(2), e02504-20 (2021).","journal-title":"J. Clin. Microbiol."},{"key":"21317_CR19","doi-asserted-by":"publisher","first-page":"100313","DOI":"10.1016\/j.onehlt.2021.100313","volume":"13","author":"CWE Embregts","year":"2021","unstructured":"Embregts, C. W. E. et al. Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test. One Health 13, 100313 (2021).","journal-title":"One Health"},{"key":"21317_CR20","unstructured":"Dynamiker. Dynamiker SARS-CoV-2 Neutralization Antibody ELISA Assay. (2021) https:\/\/en.dynamiker.com\/index\/index\/pro_info\/aid\/626.html."},{"key":"21317_CR21","doi-asserted-by":"publisher","first-page":"618651","DOI":"10.3389\/fcvm.2020.618651","volume":"7","author":"JM Condor Capcha","year":"2021","unstructured":"Condor Capcha, J. M. et al. Generation of SARS-CoV-2 spike pseudotyped virus for viral entry and neutralization assays: A 1-week protocol. Front. Cardiovasc. Med. 7, 618651 (2021).","journal-title":"Front. Cardiovasc. Med."},{"issue":"11","key":"21317_CR22","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1038\/s41596-020-0394-5","volume":"15","author":"J Nie","year":"2020","unstructured":"Nie, J. et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat. Protoc. 15(11), 3699\u20133715 (2020).","journal-title":"Nat. Protoc."},{"issue":"9","key":"21317_CR23","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1097\/JTO.0b013e3181ec173d","volume":"5","author":"JN Mandrekar","year":"2010","unstructured":"Mandrekar, J. N. Receiver operating characteristic curve in diagnostic test assessment. J. Thorac. Oncol. 5(9), 1315\u20131316 (2010).","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"21317_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/sim.2993","volume":"27","author":"EF Schisterman","year":"2008","unstructured":"Schisterman, E. F. et al. Youden Index and the optimal threshold for markers with mass at zero. Stat. Med. 27(2), 297\u2013315 (2008).","journal-title":"Stat. Med."},{"key":"21317_CR25","doi-asserted-by":"publisher","first-page":"3762651","DOI":"10.1155\/2017\/3762651","volume":"2017","author":"I Unal","year":"2017","unstructured":"Unal, I. Defining an optimal cut-point value in ROC analysis: An alternative approach. Comput. Math. Methods Med. 2017, 3762651 (2017).","journal-title":"Comput. Math. Methods Med."},{"issue":"10","key":"21317_CR26","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/s41587-020-0659-0","volume":"38","author":"JD Whitman","year":"2020","unstructured":"Whitman, J. D. et al. Evaluation of SARS-CoV-2 serology assays reveals a range of test performance. Nat. Biotechnol. 38(10), 1174\u20131183 (2020).","journal-title":"Nat. Biotechnol."},{"key":"21317_CR27","doi-asserted-by":"publisher","first-page":"114297","DOI":"10.1016\/j.jviromet.2021.114297","volume":"299","author":"A Kr\u00fcttgen","year":"2022","unstructured":"Kr\u00fcttgen, A. et al. Two novel SARS-CoV-2 surrogate virus neutralization assays are suitable for assessing successful immunization with mRNA-1273. J. Virol. Methods 299, 114297 (2022).","journal-title":"J. Virol. Methods"},{"key":"21317_CR28","doi-asserted-by":"publisher","first-page":"114122","DOI":"10.1016\/j.jviromet.2021.114122","volume":"292","author":"K M\u00fcller","year":"2021","unstructured":"M\u00fcller, K. et al. Comparison of two commercial surrogate ELISAs to detect a neutralising antibody response to SARS-CoV-2. J. Virol. Methods 292, 114122 (2021).","journal-title":"J. Virol. Methods"},{"issue":"5","key":"21317_CR29","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jinf.2021.03.010","volume":"82","author":"MJ Murray","year":"2021","unstructured":"Murray, M. J. et al. Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay. J. Infect. 82(5), 170\u2013177 (2021).","journal-title":"J. Infect."},{"issue":"4","key":"21317_CR30","doi-asserted-by":"publisher","first-page":"e02438-20","DOI":"10.1128\/JCM.02438-20","volume":"59","author":"SC Taylor","year":"2021","unstructured":"Taylor, S. C. et al. A new SARS-CoV-2 dual-purpose serology test: Highly accurate infection tracing and neutralizing antibody response detection. J. Clin. Microbiol. 59(4), e02438-20 (2021).","journal-title":"J. Clin. Microbiol."},{"issue":"1","key":"21317_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12879-022-07141-8","volume":"22","author":"M Li","year":"2022","unstructured":"Li, M. et al. Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world. BMC Infect. Dis. 22(1), 157 (2022).","journal-title":"BMC Infect. Dis."},{"issue":"11","key":"21317_CR32","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1172\/JCI142004","volume":"130","author":"SL Klein","year":"2020","unstructured":"Klein, S. L. et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J. Clin. Investig. 130(11), 6141\u20136150 (2020).","journal-title":"J. Clin. Investig."},{"key":"21317_CR33","doi-asserted-by":"publisher","first-page":"104984","DOI":"10.1016\/j.jcv.2021.104984","volume":"144","author":"B Fischer","year":"2021","unstructured":"Fischer, B. et al. A combined strategy to detect plasma samples reliably with high anti-SARS-CoV-2 neutralizing antibody titers in routine laboratories. J. Clin. Virol. 144, 104984 (2021).","journal-title":"J. Clin. Virol."},{"key":"21317_CR34","doi-asserted-by":"crossref","unstructured":"Saker, K. et al. Evaluation of commercial anti-SARS-CoV-2 neutralizing antibody assays in seropositive subjects. medRxiv 2022.01.04.22268652 (2022).","DOI":"10.1101\/2022.01.04.22268652"},{"issue":"4","key":"21317_CR35","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/cid\/ciab646","volume":"74","author":"X Chen","year":"2022","unstructured":"Chen, X. et al. Neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants induced by natural infection or vaccination: A systematic review and pooled analysis. Clin. Infect. Dis. 74(4), 734\u2013742 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"21317_CR36","doi-asserted-by":"publisher","first-page":"103972","DOI":"10.1016\/j.ebiom.2022.103972","volume":"78","author":"NA Muena","year":"2022","unstructured":"Muena, N. A. et al. Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in na\u00efve and previously infected individuals. EBioMedicine 78, 103972 (2022).","journal-title":"EBioMedicine"},{"issue":"5","key":"21317_CR37","doi-asserted-by":"publisher","first-page":"110336","DOI":"10.1016\/j.celrep.2022.110336","volume":"38","author":"TM Narowski","year":"2022","unstructured":"Narowski, T. M. et al. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people. Cell Rep. 38(5), 110336 (2022).","journal-title":"Cell Rep."},{"issue":"600","key":"21317_CR38","doi-asserted-by":"publisher","first-page":"eabi9915","DOI":"10.1126\/scitranslmed.abi9915","volume":"13","author":"AJ Greaney","year":"2021","unstructured":"Greaney, A. J. et al. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. Sci. Transl. Med. 13(600), eabi9915 (2021).","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"21317_CR39","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.it.2020.03.007","volume":"41","author":"S Jiang","year":"2020","unstructured":"Jiang, S., Hillyer, C. & Du, L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 41(5), 355\u2013359 (2020).","journal-title":"Trends Immunol."},{"issue":"24","key":"21317_CR40","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.1016\/j.febslet.2006.08.085","volume":"580","author":"F Zeng","year":"2006","unstructured":"Zeng, F. et al. Quantitative comparison of the efficiency of antibodies against S1 and S2 subunit of SARS coronavirus spike protein in virus neutralization and blocking of receptor binding: Implications for the functional roles of S2 subunit. FEBS Lett. 580(24), 5612\u20135620 (2006).","journal-title":"FEBS Lett."},{"issue":"48","key":"21317_CR41","doi-asserted-by":"publisher","first-page":"eabc8413","DOI":"10.1126\/sciimmunol.abc8413","volume":"5","author":"L Premkumar","year":"2020","unstructured":"Premkumar, L. et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci. Immunol. 5(48), eabc8413 (2020).","journal-title":"Sci. Immunol."},{"issue":"7821","key":"21317_CR42","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","volume":"584","author":"DF Robbiani","year":"2020","unstructured":"Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584(7821), 437\u2013442 (2020).","journal-title":"Nature"},{"issue":"1","key":"21317_CR43","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.1038\/s41598-021-84913-3","volume":"11","author":"MG Noval","year":"2021","unstructured":"Noval, M. G. et al. Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities. Sci. Rep. 11(1), 5538 (2021).","journal-title":"Sci. Rep."},{"issue":"1","key":"21317_CR44","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1038\/s41598-022-07849-2","volume":"12","author":"B S\u00e1nchez-Sendra","year":"2022","unstructured":"S\u00e1nchez-Sendra, B. et al. Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents. Sci. Rep. 12(1), 3788 (2022).","journal-title":"Sci. Rep."},{"issue":"9","key":"21317_CR45","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.cell.2022.03.019","volume":"185","author":"V Servellita","year":"2022","unstructured":"Servellita, V. et al. Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. Cell 185(9), 1539-1548.e5 (2022).","journal-title":"Cell"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21317-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21317-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21317-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T20:26:28Z","timestamp":1667939188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21317-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["21317"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-21317-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"assertion":[{"value":"2 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19020"}}